GSK plc GSK:NYSE

RT Quote | Last NASDAQ LS, VOL From CTA | USD

After Hours: Last | 6:28 PM EST

36.58

+0.26 (+0.72%)

Volume

18,569

36.32

+0.15 (+0.41%)

Volume

3,369,244

52 week range

28.47 - 46.97

Open36.56
Day High36.59
Day Low36.23
Prev Close36.17
52 Week High46.97
52 Week High Date04/11/22
52 Week Low28.47
52 Week Low Date09/26/22

Key Stats

Market Cap74.359B
Shares Out2.05B
10 Day Average Volume4.67M
Dividend1.39
Dividend Yield3.82%
Beta0.67
YTD % Change3.36

KEY STATS

Open36.56
Day High36.59
Day Low36.23
Prev Close36.17
52 Week High46.97
52 Week High Date04/11/22
52 Week Low28.47
52 Week Low Date09/26/22
Market Cap74.359B
Shares Out2.05B
10 Day Average Volume4.67M
Dividend1.39
Dividend Yield3.82%
Beta0.67
YTD % Change3.36

RATIOS/PROFITABILITY

EPS (TTM)2.54
P/E (TTM)14.31
Fwd P/E (NTM)10.62
EBITDA (TTM)9.827B
ROE (TTM)34.78%
Revenue (TTM)35.312B
Gross Margin (TTM)67.98%
Net Margin (TTM)16.78%
Debt To Equity (MRQ)198.03%

EVENTS

Earnings Date04/26/2023
Ex Div Date02/23/2023
Div Amount0.3404
Split Date-
Split Factor-

Latest On GSK plc

Pro Picks: Watch all of Monday's big stock calls on CNBCFebruary 6, 2023CNBC.com
Investor Sarat Sethi said he is buying into this 'unloved' pharma stockFebruary 6, 2023CNBC.com
RSV vaccine: Moderna, Pfizer start a new FDA approval raceJanuary 18, 2023CNBC.com
Cramer's lightning round: I think Boeing is goodJanuary 17, 2023CNBC.com

Content From Our Affiliates

GSK, Cytel enter three-year agreement to expand Solara deploymentFebruary 7, 2023TipRanks
GSK price target raised to 1,400 GBp from 1,350 GBp at JPMorganFebruary 2, 2023TipRanks
Akebia should update on vadadustat FDA process in next month, says Piper SandlerFebruary 2, 2023TipRanks
GSK reports Jesduvroq approved by FDA for anemia of CKD in adults on dialysisFebruary 2, 2023TipRanks
Ionis Pharmaceuticals: GSK advances bepirovirsen into Phase 3 developmentFebruary 1, 2023TipRanks

Profile

GSK plc is a global biopharma company. The Company makes vaccines and specialty medicines to prevent and treat disease. Its segments include Commercial Operations and Research and Development. It develops cancer medicines for patients, including ovarian cancer, endometrial cancer, and multiple myeloma. It has developed a new monoclonal antibody treatment for COVID-19. Its product areas include vaccines, specialty medicines, and general medicines. Its vaccine portfolio...

Jonathan Symonds CBE

Independent Non-Executive Chairman of the Board

Emma Walmsley

Chief Executive Officer, Executive Director

Iain Mackay

Chief Financial Officer, Executive Director

Address